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We read with interest the recent article by Lisette Kunz et al. in the European Respiratory 
Journal (ERJ), and the appropriately questioning accompanying editorial by Peter Calverley 
in the same issue, considering airway inflammation and effects of inhaled corticosteroids 
(ICS) in chronic obstructive pulmonary disease (COPD) (1). Understanding COPD pathology 
is a hugely important area and it is encouraging that leading respiratory journals are 
recognising this. We would like to suggest that a broader discussion of new insights into 
COPD pathology might have been appropriate. Thus, a more integrated consideration of 
overall airway wall cellularity, vascularity, epithelial mesenchymal transition (EMT), and the 
effects of ICS on these in COPD is urgently needed to aid discussion of this devastating 
pathophysiology.   
 
We have previously published that total airway wall cellularity is actually decreased in 
smokers and COPD patients (2). This change is strongly associated with smoking history and 
tended to approach normal levels in COPD ex-smokers. We ourselves initially found this 
surprising because it is at variance with the current “COPD-establishment” paradigm that the 
pathology is characterised by chronic inflammation in the airways including the airway wall 
(2), but there are in fact few if any other reports on total airway wall cellularity in the 
literature. We subsequently found this to be a consistent result over some years of work, and 
are in the process of publishing a confirmatory follow up study (paper in Press, Respirology), 
indicating that both small and large airway walls in smokers and mild-moderate COPD 
patients were hypo-cellular.  
 
Most of the studies in the COPD literature on this area do not seem to take into account total 
airway wall cellularity, which could have profound implications for the interpretation of 
differential cell counts. The GLUCOLD study group have a strong and long standing 
collective history of quantitative studies of airway biopsies. We wonder therefore whether 
Kunz et al have any information either from their current study or cumulative experience, 
regarding this big-picture issue to help contextualise their findings? We also noted that their 
data seemed to indicate that the number of CD4+ cells in the airway wall out-numbered the 
CD8+ counts; this would be a finding which hasn’t been shown before to our knowledge, and 
is in marked contrast to our experience in COPD. We therefore wonder if the authors have 
any comment regarding their unusual CD4+ lymphocyte counts? 
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Active EMT and epithelial reticular basement membrane (Rbm) fragmentation and hyper-
vascularity (with contrasting lamina propria hypo-vascularity) have also been shown to be 
present in the airway wall in COPD, and we have hypothesised that these changes represent 
fundamentally important aspects of COPD pathology (3, 4) and may allow a unified 
understanding of important consequences of basal stem cell reprogramming. Insights into 
EMT and associated pathology in COPD may have the potential to be translated into a new 
paradigm for earlier therapy and improved clinical outcomes and may contribute to the very 
active debates around ICS therapy in COPD. With respect to this, do Kunz et al, have any 
information from their current study regarding ICS effects on EMT, airway wall vascularity 
or other manifestations of basal cell reprogramming? 
 
We believe there is a need for debate, and further in-depth studies of what are the 
fundamental issues with this disease; as Peter Calverley suggests, we have made some 
progress, but need more. Even major published overviews of COPD largely ignore such 
important aspects of the disease as the realization that fifty percent of small airways have 
been obliterated by airway remodeling before the FEV1 has even changed (5), and the lethal 
association between even early/mild COPD and lung cancer. It is biologically plausible that 
the link between cancer and COPD, which is an independent risk apart from smoking, may be 
related to parameters that could be more widely measured, such as markers of EMT or 
epithelial hyper-vascularity. Progression of this conversation will be helped by discussion of 
the different approaches from centers that have made great efforts to perform translational 
quantitative studies in COPD patient airways. We would be very interested in further debate, 
and indeed collaboration, between centers with access to and experience of working with 
human COPD tissue, in the spirit of the excellent article by Ratko Djukanović et al, which 
came out in the same edition of the ERJ. The leading respiratory journals have a key capacity 
to promote this approach through supporting novel descriptive human tissue studies that 
provide new insights and paradigms, even when at variance with the respiratory 
establishment`s current “tenets”. 
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